ArticleMolecular neurobiology2026
Chalcone-based Pyrazoline Derivatives as Modulators of Neuroinflammatory and Redox Pathways in Experimental Epilepsy.
Article in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Epilepsy is a chronic neurological condition characterized by complex pathophysiological interactions involving oxidative stress (OS) and neuroinflammation. In this study, the neuroprotective effects of chalcone-based pyrazoline derivatives (CCA-326, CCA-334, CCD-326, and CCD-334) are investigated in a penicillin-induced epilepsy model in rats. The ELISE method is used to measure the effects of these compounds on the plasma and brain levels of cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), nuclear factor-kappa B (NF-κB), Kelch-like ECH-associated protein 1 (KEAP1), and nuclear factor erythroid 2-related factor 2 (NRF2). Total antioxidant status (TAS) and total oxidant status (TOS) were determined using colorimetric methods. CCA-326 and CCA-334 significantly reduces NF-κB, COX-2, and 5-LOX levels, increases NRF2 expression and TAS levels, and supports the activation of the endogenous antioxidant system by inducing a noticeable decrease in KEAP1 levels. These results suggest that CCA-334 stands out as a promising compound for further investigation targeting oxidative stress and inflammation in epilepsy, and that chalcone-based pyrazoline derivatives may modulate key inflammatory and redox pathways involved in epileptogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.